ストックスクリーナーアプリを入手
27.32
2.39%
-0.67
アフターアワーズ：
27.26
-0.06
-0.22%
前日終値:
$27.99
開ける：
$27.9
24時間の取引高:
1.02M
Relative Volume:
0.53
時価総額：
$5.16B
収益：
$217.77M
当期純損益:
$-438.86M
株価収益率:
-7.0051
EPS:
-3.9
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
-1.62%
1か月 パフォーマンス:
+0.85%
6か月 パフォーマンス:
+7.86%
1年 パフォーマンス:
-32.33%
1日の値動き範囲:
$27.23
$27.99
1週間の範囲:
$27.23
$28.84
52週間の値動き範囲:
$21.62
$41.04
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
27.32 | 5.16B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail
Is This Biotech Stock With 150% Upside a Buy Now? - TradingView
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Principal Financial Group Inc. - MarketBeat
BridgeBio price target raised to $50 from $45 at Evercore ISI - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
Bridgebio’s Attruby FDA nod boosts stock; 10 November approvals - BioWorld Online
How To Trade (BBIO) - Stock Traders Daily
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - BioSpace
Geode Capital Management LLC Purchases 123,540 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Wellington Management Group LLP Decreases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma's SWOT analysis: innovative pipeline drives stock potential - Investing.com
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
HC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Holdings Lifted by Barclays PLC - MarketBeat
BridgeBio's SWOT analysis: genetic disease specialist's stock poised for growth By Investing.com - Investing.com South Africa
BridgeBio's SWOT analysis: genetic disease specialist's stock poised for growth - Investing.com Australia
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is Exome Asset Management LLC's 3rd Largest Position - MarketBeat
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP - BioCentury
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Yahoo Finance
Learn to Evaluate (BBIO) using the Charts - Stock Traders Daily
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Frazier Life Sciences Management L.P. Buys 127,853 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market: Size, Share, - openPR
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 8.4%Should You Buy? - MarketBeat
Polar Asset Management Partners Inc. Buys Shares of 50,500 BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Janus Henderson Group PLC Increases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Melqart Asset Management UK Ltd Grows Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HighVista Strategies LLC Acquires 24,482 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Unnatural Products Announces BridgeBio Exercises Option to - GlobeNewswire
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for - The Bakersfield Californian
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology - Yahoo Finance
Erste Asset Management GmbH Invests $3.50 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma (BBIO) Stock Surges on FDA Approval of Lead Treatment - Nasdaq
BridgeBio Pharma (FRA:2CL) Price-to-Operating-Cash-Flow : (As of Dec. 01, 2024) - GuruFocus.com
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease - AOL
The week in pharma: action, reaction and insight – week to November 29 - The Pharma Letter
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More - Yahoo Finance
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug - MSN
Intech Investment Management LLC Makes New Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition - MSN
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug - MSN
HC Wainwright Has Optimistic Outlook of BBIO FY2024 Earnings - MarketBeat
Research Analysts Offer Predictions for BBIO FY2024 Earnings - MarketBeat
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug - MSN
BridgeBio Pharma (FRA:2CL) Total Liabilities : €1,696.9 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby - Marketscreener.com
BridgeBio: Shares Surge as Attruby Gains FDA Approval; Slightly Raising Our Fair Value Estimate - Morningstar
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability - Morningstar
What is Leerink Partnrs' Estimate for BBIO FY2027 Earnings? - MarketBeat
BridgeBio price target raised to $45 from $42 at BofA - Yahoo Finance
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.76%
1.06%
大文字化:
|
ボリューム (24 時間):